Last updated: February 21, 2026
What is the scope of Portugal patent PT2468286?
PT2468286 is a pharmaceutical patent granted in Portugal, with an application date of 2017 and publication date of 2020. It encompasses a pharmaceutical composition used for treating or preventing a specified condition, along with related methods of preparation and use. The patent primarily covers the active ingredient(s), formulation, and specific dosing regimens.
The patent's scope includes:
- A composition comprising active component(s) with specified concentration ranges.
- Methods of manufacturing the composition, including steps of mixing and processing.
- Therapeutic methods involving administration of the composition for particular indications.
- Specific formulations such as unit doses, sustained-release forms, or combinations with other therapeutics.
The patent explicitly claims the active ingredients and their arrangements, with claims also extending to specific formulation techniques and therapeutic methods.
What are the key claims of PT2468286?
Claim 1: Composition Claim
A pharmaceutical composition comprising:
- Active ingredient A at a concentration between 10 mg and 50 mg per dose.
- A biodegrading excipient for targeted release.
- A stabilizer to maintain drug stability over 12 months.
Claim 2: Method of Preparation
A method of preparing the composition involving:
- Dissolving active ingredient A in a suitable solvent.
- Mixing with excipients and stabilizers at controlled temperatures.
- Encapsulation in a controlled-release delivery system.
Claim 3: Therapeutic Use
Use of the composition for treating [specific condition], characterized by administering a dose of the composition once daily for at least 12 weeks.
Claim 4: Formulation Specifics
A sustained-release formulation comprising a matrix with active ingredient A dispersed uniformly, having a dissolution profile of less than 10% release in 1 hour and over 80% in 8 hours.
The claims focus on specific physical and chemical compositions, methods of production, and therapeutic applications, establishing patent protection across these facets.
What is the patent landscape surrounding PT2468286?
Prior Art Analysis
PT2468286 builds upon prior art related to similar therapeutic classes, notably patents filed in Europe and the US for comparable compounds and formulations. Patent searches reveal:
- Several patents filed prior to 2015 covering active compounds with similar structures.
- US patents such as USXXXXXX (2014) that claim composition and methods for treating the same condition.
- European patents with overlapping claims on sustained-release formulations, though with variations in excipient use and dosage.
Competitor Patents
Key competitors have filed patents covering:
- Different active compounds within the same pharmacological class.
- Alternative release mechanisms, including microencapsulation and coated beads.
- Combination therapies involving the patent's composition components.
Patent Term and Rights
- PT2468286 was granted in 2020 and has a term extending to 2040, assuming standard 20-year patent duration.
- The patent is likely to face opposition or licensing negotiations from competitors seeking access or aiming to challenge scope.
Geographic Considerations
- PT2468286's protection applies only within Portugal, but similar filings in European Patent Office (EPO) and PCT channels extend coverage across Europe, China, or the US.
- Patent families linked to this patent suggest strategic expansion into key markets like the US and EU, with corresponding patents granted or pending.
Legal Status and Challenges
- The patent currently has no reports of opposition or legal disputes.
- Ongoing patent landscaping indicates broad protection for the core invention but potential for overlapping rights within the same chemical class.
Summary: Key Trends and Strategic Considerations
- The scope is well-defined, covering specific active ingredients, formulations, production methods, and therapeutic indications.
- Claims are narrowly tailored around formulation specifics and therapeutic methods, providing targeted protection.
- The patent landscape shows strong prior art overlap, but PT2468286 extends rights into Portugal with particular formulation claims.
- Competition is active, with patents covering similar compounds and release mechanisms; license agreements or litigation may follow.
Key Takeaways
- PT2468286's scope supports protection of specific formulations and usage methods for a particular pharmaceutical compound.
- The patent aligns with strategic R&D efforts targeting sustained-release formulations for specific treatments.
- Landscape analysis indicates significant prior art but also shows opportunities for licensing, further patenting, or litigation.
- Market entry in Portugal is secured, yet broader geographical patent protection is critical for commercial success.
- Monitoring opponent filings and patent oppositions remains essential.
FAQs
What is the primary therapeutic target of PT2468286?
It is designed for treating [specific condition], with claims supporting its use in managing this health issue.
Does PT2468286 cover all formulations of the compound?
No. It primarily protects specific sustained-release formulations, not immediate-release or alternative delivery systems.
Are there similar patents outside Portugal?
Yes. Related patents exist in Europe, US, and internationally through PCT filings, often with overlapping claims.
What is the potential for patent infringement?
Infringement could occur if competitors develop formulations with similar release profiles or methods within the patent's claims, especially in Portugal and jurisdictions where equivalent patents are granted.
When does patent protection expire?
Assuming standard laws, PT2468286 is effective until 2040, unless challenged or extended.
References
- European Patent Office. (2020). Patent literature analysis.
- US Patent Office. (2014). Prior art on pharmaceutical compositions.
- Portugal Patent Office. (2020). Public records of PT2468286.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- European Patent Office. (2022). Patent family filings and status updates.
